Interleukin 6 Inhibitors Pipeline Insight
DelveInsight’s, “Interleukin 6 Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Interleukin 6 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interleukin 6 Inhibitors Understanding
Interleukin 6 Inhibitors: Overview
Interleukin-6 (IL-6) is a protein produced by various cells. It helps regulate immune responses, which makes the IL-6 test potentially useful as a marker of immune system activation. IL-6 can be elevated with inflammation, infection, autoimmune disorders, cardiovascular diseases, and some cancers. The test measures the amount of IL-6 in the blood. Interleukin-6 is one of a large group of molecules called cytokines. Cytokines have multiple roles to play within the body and act especially within the immune system to help direct the body’s immune response. They are a part of the “inflammatory cascade” that involves the coordinated, sequential activation of immune response pathways. Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. Hence, anti-IL6 agents have been sought. In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors.
The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 6 Inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin 6 Inhibitors.
Interleukin 6 Inhibitors Emerging Drugs Chapters
This segment of the Interleukin 6 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin 6 Inhibitors Emerging Drugs
Ziltivekimab: Novo Nordisk
Ziltivekimab is a fully human monoclonal antibody designed to lower systemic inflammation through inhibition of IL-6 (a pro-inflammatory cytokine with a causal role in atherosclerosis). With its extended half-life technology, ziltivekimab has been designed to enable once-monthly administration by subcutaneous (SC) injection. Ziltivekimab is being developed by Novo Nordisk following the acquisition of Corvidia Therapeutics, announced in June 2020.
Siltuximab: EUSA Pharma
Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, of which potentially there may be a role in patients with COVID-19. It is currently approved by the FDA and the European Medicines Agency (EMA) as well as regulatory bodies in a number of other jurisdictions worldwide, for the treatment of patients with multicentric Castleman disease (MCD). Currently, it is in phase 3 stage of clinical trial evaluation to treat SARS-CoV-2 acute respiratory disease.
Further product details are provided in the report……..
Interleukin 6 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin 6 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Interleukin 6 Inhibitors
There are approx. 15+ key companies which are developing the Interleukin 6 Inhibitors. The companies which have their Interleukin 6 Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Interleukin 6 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Interleukin 6 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 6 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 6 Inhibitors drugs.
Interleukin 6 Inhibitors Report Insights
- Interleukin 6 Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Interleukin 6 Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Interleukin 6 Inhibitors drugs?
- How many Interleukin 6 Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interleukin 6 Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin 6 Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interleukin 6 Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?